Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers’ Target?
We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...
North American Morning Briefing: Stock Futures Struggle After Fed-Fueled Rally
FedEx cut its outlook after posting lower quarterly profit and revenue. Its stock fell 13%; shares of rival UPS also fell. Ford and General Motors fell after Mercedes-Benz trimmed its forecasts and ...
MarketBeat on MSN2d
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Every single member of the board just resigned from DNA tester 23andMe
Following a monthslong battle over CEO Anne Wojcicki’s plans to take 23andMe private, all seven members of its board resigned ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Fierce Healthcare4d
Noom to offer compounded GLP-1 drug to rival pricey branded weight loss meds
Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more ...
Should You Invest in This Under-the-Radar Weight Loss Stock?
However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...